BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) unveiled its unaudited H1 interim results, with £4.5mln of cash and equivalents to help execute its immediate plans over the next year.
The biotechnology company that develops cancer therapies said it focused on delivering value propositions built on “ unrivalled” expertise and knowledge, as well as strengthening its intellectual property with more patent applications.
It invested £1.2mln into research and development in the six months ended 30 June, while establishing a “highly experienced” scientific team, increasing its internal capabilities, the company said in a statement.
BiVictriX fast-tracked the development of its novel "twin antigen pair" discovery engine, providing further opportunities to move it into higher value areas across a broad range of solid tumour indications.
Tiffany Thorn, chief executive, commented: "This year has seen significant progress across our pipeline, as we remain focused on optimising BVX001 and establishing ourselves as leaders in the development of highly selective, next-generation cancer therapeutics.
“Our focus continues to be on finding the best treatments for targeting the cancer, not the patient, and I am proud of the advancements we have made and continue to make.”